IMDX — Insight Molecular Diagnostics Inc.
NASDAQ · Healthcare · Diagnostics & Research
$3.95
+$0.11 (+2.86%)
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on NASDAQ. It is led by Joshua Riggs, based in 2 International Plaza Dr., Nashville, TN, United States, 37217, with about 46 employees. Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Irvine, California.
Latest reported IMDX revenue for 2025-09-30 was $260.0K. Net income was -$10.9M. Revenue was down 49.8% from 2025-06-30 to 2025-09-30.
Use this IMDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Insight Molecular Diagnostics Inc. even when a live quote feed is slow.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Irvine, California.
IMDX Key Statistics
Market Cap
$0.00M
Volume
155,881
Previous Close
$4.32
Day Range
$4.35 – $4.53
EPS
-$4.66
Revenue
$1.88M
Net Income
-$60.66M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+25.1%
Profit Margin
-3225.0%
Employees
46
IMDX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.88M | $1.50M | $958.00K | $3.59M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$60.66M | -$27.78M | -$72.90M | -$35.88M |
| EPS (Diluted) | -$4.66 | -$3.75 | -$13.25 | $0.00 |
Total Assets
$35.08M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$8.64M
Operating Cash Flow
-$20.71M
Free Cash Flow
$0.00
Insight Molecular Diagnostics Inc. Company Information
- President, CEO & Director
- Joshua Riggs
- Headquarters
- 2 International Plaza Dr., Nashville, TN, United States, 37217
- Website
- imdxinc.com
- Phone
- 949 409 7600
- IPO / Founded
- 2016-01-04
- Sector
- Healthcare
- Industry
- Diagnostics & Research